Bristol-Myers Squibb Company (BMY) — Analyst outlook / Analyst consensus target is. Based on 41 analyst ratings, the consensus is bullish — 19 Buy, 20 Hold, 2 Sell.
The consensus price target is $62.73 (low: $40.00, high: $75.00), representing an upside of 8% from the current price $58.08.
Analysts estimate Earnings Per Share (EPS) of $0.92 and revenue of $47.51B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.41 vs est $0.92 (missed -581.8%). 2025: actual $3.46 vs est $6.11 (missed -43.4%). Analyst accuracy: 1%.
BMY Stock — 12-Month Price Forecast
$62.73
▲ +8.01% Upside
Average Price Target
Based on 41 Wall Street analysts offering 12-month price targets for Bristol-Myers Squibb Company, the average price target is $62.73, with a high forecast of $75.00, and a low forecast of $40.00.
The average price target represents a +8.01% change from the last price of $58.08.
Highest Price Target
$75.00
Average Price Target
$62.73
Lowest Price Target
$40.00
BMY Analyst Ratings
Hold
Based on 41 analysts giving stock ratings to Bristol-Myers Squibb Company in the past 3 months
EPS Estimates — BMY
1%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$4.41
vs Est $0.92
▼ 120.8% off
2025
Actual $3.46
vs Est $6.11
▼ 76.7% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — BMY
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $48.300B
vs Est $47.513B
▲ 1.6% off
2025
Actual $48.194B
vs Est $47.990B
▲ 0.4% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
